Portola Pharmaceuticals (PTLA) Getting Somewhat Favorable News Coverage, Report Finds
News articles about Portola Pharmaceuticals (NASDAQ:PTLA) have trended somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.386989767972 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Brokerages Expect Portola Pharmaceuticals Inc (PTLA) to Post -$1.54 Earnings Per Share (americanbankingnews.com)
- Portola Pharmaceuticals: What The Latest Developments Regarding AndexXA Entail? – Seeking Alpha (seekingalpha.com)
- Portola Pharmaceuticals, Inc. (PTLA) expected to touch 78.40% EPS growth for coming year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Portola Pharmaceuticals (finance.yahoo.com)
- Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences (finance.yahoo.com)
A number of equities research analysts recently weighed in on PTLA shares. BidaskClub raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. ValuEngine downgraded shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. William Blair reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a research note on Thursday, March 1st. Morgan Stanley downgraded shares of Portola Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $65.00 target price for the company. in a research note on Thursday, March 1st. Finally, Oppenheimer set a $67.00 target price on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. Portola Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $64.90.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.46) by $0.05. Portola Pharmaceuticals had a negative net margin of 1,268.34% and a negative return on equity of 108.43%. The firm had revenue of $9.80 million during the quarter, compared to the consensus estimate of $3.71 million. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. The business’s quarterly revenue was down 28.4% on a year-over-year basis. equities research analysts forecast that Portola Pharmaceuticals will post -4.91 EPS for the current fiscal year.
In other news, Director Henry Ward Wolff sold 12,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.50% of the stock is currently owned by corporate insiders.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.